Home Drug IndexClinical Monograph

Trimetazidine Uses, Dosage, Side Effects & Warnings | DrugsAtlas

Authoritative Clinical Reference

Therapeutic Class

Antianginal Agent

Subclass

Metabolic Modulator (Fatty Acid Oxidation Inhibitor)

Speciality

Cardiology

Schedule (India)

Schedule H

Routes

Oral

Formulations

Tablets (Immediate-release): 20 mg
Tablets (Modified-release): 35 mg

Adult indications

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

1. Chronic Stable Angina Pectoris (Adjunctive Therapy)

⚠️ Not for monotherapy — Always use as add-on to conventional antianginal agents (beta-blockers, calcium channel blockers, nitrates)

Immediate-Release Formulation (20 mg tablet):

Parameter	Dose
Starting dose	20 mg orally three times daily with meals
Titration	Not applicable — fixed dosing regimen
Usual maintenance dose	60 mg/day in three divided doses
Maximum dose	60 mg/day

Modified-Release Formulation (35 mg MR tablet):

Parameter	Dose
Starting dose	35 mg orally twice daily (morning and evening with meals)
Titration	Not applicable — fixed dosing regimen
Usual maintenance dose	70 mg/day in two divided doses
Maximum dose	70 mg/day

Clinical Notes:

Must be taken with food to improve absorption
Does not affect heart rate or blood pressure — hemodynamically neutral
Not effective for acute angina attacks — no rescue use
Mechanism: Shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation, improving myocardial efficiency under ischaemic conditions
Benefits typically seen after 2–4 weeks of regular use
Particularly useful when beta-blockers or CCBs are contraindicated, poorly tolerated, or provide inadequate symptom control

Secondary Indications – Adults (Off-label)

Indication	Dose	Duration	Supervision	Evidence Basis
Tinnitus and Vertigo of Vascular/Ischaemic Origin (OFF-LABEL)	20 mg orally twice to three times daily OR 35 mg MR twice daily	2–3 months trial; discontinue if no benefit	ENT specialist recommended	Indian specialist practice; limited controlled trial data
Chorioretinal Disorders with Vascular Component (including Retinitis Pigmentosa) (OFF-LABEL)	35 mg MR orally twice daily	Long-term as tolerated	Specialist only (Ophthalmology)	Limited evidence; used in some Indian ophthalmic protocols
Heart Failure with Reduced Ejection Fraction (HFrEF) — Adjunct (OFF-LABEL)	35 mg MR orally twice daily	Long-term	Specialist only (Cardiology)	Some RCTs suggest improvement in exercise capacity; not standard practice; Indian Heart Failure Society does not include as routine recommendation

Paediatric indications

PAEDIATRIC DOSING (Specialist Only)

Primary Indications

Not applicable — no approved paediatric indications in India.

Secondary Indications – Paediatrics (Off-label)

Not recommended — safety and efficacy not established in patients below 18 years of age.

Age Restriction:

Not recommended in children or adolescents under 18 years
Off-label use is discouraged due to complete lack of paediatric pharmacokinetic and safety data
Use only under exceptional circumstances with specialist supervision (e.g., rare paediatric vasculopathies)

Renal Adjustments

eGFR (mL/min/1.73 m²)	Recommendation
≥60	No dose adjustment required
30–59	Use with caution; consider reduced dosing (35 mg once daily or 20 mg twice daily); monitor for adverse effects
<30	Avoid — insufficient clearance data; increased risk of accumulation and adverse effects
Haemodialysis	Avoid — no data on dialysability; likely not removed effectively

Additional Notes:

Trimetazidine is predominantly renally excreted
Assess renal function (serum creatinine, eGFR) before initiating therapy

Hepatic adjustment

Contraindications

Known hypersensitivity to trimetazidine dihydrochloride or any excipients
Parkinson's disease
Parkinsonian symptoms (tremor, rigidity, akinesia, bradykinesia)
Restless legs syndrome
Other movement disorders
Severe renal impairment (eGFR <30 mL/min/1.73 m²)

Cautions

Elderly patients (≥65 years) — significantly increased risk of movement disorders; careful neurological assessment required before and during treatment
Moderate renal impairment (eGFR 30–59) — dose reduction may be needed
History of extrapyramidal symptoms or falls
Concurrent use with dopamine antagonists (may increase risk of movement disorders)
Not to be used for acute angina treatment or as initial therapy for unstable angina/MI
Patients should be informed to report any movement abnormalities immediately

Pregnancy

Parameter	Information
Overall Safety	Safety in pregnancy not established; limited human data
Risk	Unknown; no adequate controlled studies in pregnant women
Preferred Alternatives	Unidentified
When Use May Be Justified	Only if no suitable alternative and benefit clearly outweighs potential risk; requires specialist cardiology and obstetric input
Monitoring	Fetal growth monitoring if used; maternal symptom assessment

Lactation

Parameter	Information
Compatibility	Not recommended — insufficient data on excretion in human breast milk
Expected Drug Level in Milk	Unknown; likely low based on physicochemical properties
Preferred Alternatives	Better-studied antianginal agents (beta-blockers like metoprolol) if required
Infant Monitoring	Not applicable — advised to avoid use during breastfeeding
Recommendation	Avoid breastfeeding during treatment or avoid drug during breastfeeding

Elderly

Parameter	Recommendation
Starting dose	Use lower end of dosing range; consider starting with 35 mg once daily (MR formulation) or 20 mg twice daily (IR formulation)
Titration	Titrate slowly to full dose based on tolerability over 1–2 weeks
Increased Risks	Extrapyramidal symptoms (tremor, rigidity, gait disturbance), falls, reversible Parkinsonism
Additional Precautions	Assess baseline neurological status (gait, tremor, rigidity) before initiation; regular neurological review every 6 months; assess renal function before and during therapy; discontinue immediately if movement disorders develop

Major drug interactions

Interacting Drug	Mechanism	Effect	Management
Dopamine Antagonists (metoclopramide, prochlorperazine, haloperidol, risperidone)	Additive dopamine blockade	Increased risk of extrapyramidal symptoms and Parkinsonism	Avoid combination, especially in elderly; if essential, monitor closely for movement disorders
Levodopa / Dopamine Agonists	Pharmacodynamic antagonism at dopaminergic pathways	Potential worsening of Parkinsonian symptoms; reduced efficacy of dopaminergic therapy	Contraindicated in patients with Parkinson's disease or on antiparkinsonian drugs

Moderate drug interactions

Interacting Drug	Effect	Management
Beta-blockers, Calcium Channel Blockers, Nitrates	Additive antianginal effect; theoretical synergy	Generally beneficial combination; intended use; monitor for symptomatic hypotension if adding nitrates
Antihypertensives (ACE inhibitors, ARBs, diuretics)	Potential additive hypotensive effects (though trimetazidine is haemodynamically neutral)	Monitor blood pressure; unlikely to be clinically significant
Opioid Analgesics	Additive sedation in elderly	Use with caution in elderly; monitor for excessive sedation
CNS-active Drugs (antipsychotics, antidepressants with extrapyramidal potential)	Additive risk of tremor or extrapyramidal symptoms	Monitor neurological status

Note: Trimetazidine has no significant CYP450-mediated interactions; drug interaction profile is relatively limited.

Common Adverse effects

Gastrointestinal disturbance (nausea, vomiting, dyspepsia, abdominal pain)
Dizziness
Headache
Asthenia, fatigue
Rash, pruritus
Somnolence

Serious Adverse effects

Adverse Effect	Clinical Action
Extrapyramidal Symptoms (tremor, rigidity, bradykinesia, gait instability) — dose-dependent and more common in elderly	Discontinue immediately; symptoms usually reversible within 4 months of stopping; refer to neurology if symptoms persist
Reversible Parkinsonism	Discontinue immediately; most cases resolve after stopping drug; neurology consultation recommended
Severe Hypersensitivity Reactions (angioedema, anaphylaxis — rare)	Discontinue permanently; emergency management
Thrombocytopenia (very rare)	Monitor platelet count; discontinue if significant; haematology referral
Agranulocytosis (very rare)	Discontinue immediately; haematology referral; supportive care
Fixed Drug Eruption (rare)	Discontinue; dermatology consultation

Monitoring requirements

Timing	Parameters
Baseline	Renal function (serum creatinine, eGFR); neurological examination (gait assessment, tremor evaluation, rigidity); history of movement disorders
After initiation (4–8 weeks)	Symptom response (angina frequency, exercise tolerance); neurological status (any new tremor, gait difficulty, stiffness); tolerability assessment
Long-term (every 6–12 months)	Neurological examination (especially in elderly — screen for extrapyramidal symptoms); renal function (annually or sooner if elderly or CKD); reassess need for continued therapy
If movement disorders develop	Discontinue immediately; reassess; neurology referral if symptoms persist beyond 4 months

Brands in India

Modified-Release (35 mg):

Vastarel MR™ (Serdia/Servier)
Flavedon MR™ (Serdia)
Trimetazidine MR™ (Various)
Carvidon MR™ (Sun Pharma)
Trimet MR™

Immediate-Release (20 mg):

Trimetazidine™ (Generic — various manufacturers)
Trimet™
Carvidon™

Note: Modified-release 35 mg formulation is more commonly prescribed due to twice-daily dosing convenience. Fixed-dose combinations are not commonly available.

Price range (INR)'

Formulation	Price Range	Notes
20 mg IR tablet	₹3–₹6 per tablet	Less commonly used
35 mg MR tablet	₹7–₹12 per tablet	Most commonly prescribed formulation

Regulatory: Not listed under NLEM 2022; not under NPPA price control; prices vary by brand and region

Clinical pearls

Adjunctive therapy only — Trimetazidine is never first-line or monotherapy for angina; always add to beta-blockers, CCBs, or nitrates when these provide inadequate symptom control or are limited by adverse effects
Haemodynamically neutral — Does not affect heart rate or blood pressure; particularly useful in patients with hypotension or bradycardia where beta-blockers or CCBs are problematic
Parkinsonism screening is essential — Always screen for pre-existing movement disorders before starting; contraindicated in Parkinson's disease; risk is dose-dependent and highest in elderly
Elderly require special attention — Start at lower doses; monitor neurological status regularly; discontinue immediately if tremor, gait disturbance, or rigidity develops — symptoms are usually reversible
Renal function determines eligibility — Avoid in severe renal impairment (eGFR <30); reduce dose in moderate impairment; check eGFR before and during therapy
No acute benefit — Does not relieve acute angina attacks; patients must continue to use short-acting nitrates (GTN sublingual) for breakthrough symptoms

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...